Navigation Links
Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008
Date:5/16/2008


Financial Highlights:

- 2007 Comprehensive Income increased 42% to $9.7 million

- 2007 Revenue increased 29% to $15.9 million

- 2007 Gross Margin of 76%

- Product Sales Backlog as of March 31, 2008 increased 410% to $12.2

million from $2.4 million as of December 31, 2007

SHENZHEN, China, May 16 /Xinhua-PRNewswire-FirstCall/ -- Huiheng Medical, Inc. ("Huiheng" or the "Company") (OTC Bulletin Board: HHGM), a China-based leader in the development, sales and support of radiation therapy equipment used for the treatment of cancer, announced financial results for the year ended December 31, 2007 and for the three months ended March 31, 2008.

Comments from Mr. Hui Xiaobing, Chairman & CEO

Mr. Hui commented, "We believe the market for radiation therapy in China has strong secular growth drivers in place. China's aging population, high rate of cancer incidence, and increasing demand for high-quality medical equipment and efficient healthcare services are some of the key factors we believe will contribute to the growth of the radiotherapy equipment market."

Mr. Hui concluded, "2007 was a very successful year for us, as our revenues grew by nearly 30% and our bottom line comprehensive income grew by more than 40%. We are now looking forward to 2008 and anticipating another strong year. Despite the Chinese New Year Holiday and the severe snowstorms that struck China in the first quarter, 2008 has started off strong as our revenue backlog from product sales increased to approximately $12.24 million as of March 31st, 2008 from approximately $2.4 million as of December 31, 2007."

Overview of 2007 Results

Operating revenues

For the year ended December 31, 2007, net revenues were $15.94 million, an increase of $3.59 million, or 29%, compared to $12.35 million for year ended 2006.

Total revenues from product sales were $9.53 million for 2007, an increase of $2.92 million or 44%, c
'/>"/>

SOURCE Huiheng Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Medical, technological advances prompt updating of nuclear medicine technologists scope of practice
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
4. Thermage, Inc. Announces Distribution Agreement With Eclipse Medical, Ltd.
5. Medical, Behavioral Woes Can Drive Dogs to Bite
6. ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase.
7. Sedgwick CMS and UnitedHealth Group to Develop Integrated Disability, Medical, Workers Compensation and Leave Administration Services for Employers
8. Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome
9. XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM)
10. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
11. Cardiva Medical, Inc. Appoints Two New Officers: Malcolm Farnsworth as Vice President of Finance and Chief Financial Officer and Tara Zerby as Vice President of Business Development and Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...e American Society for Gastrointestinal Endoscopy ...opy in the bariatric surgery patient. The rising p...success in surgical interventions led to a marked ...rformed in the U.S., from 13,365 in 1998 to 102,79... preoperative patient and the postoperative patien...
(Date:7/25/2008)...ent of Defense and Federal Agencies in, the execu... Phoenix is a, four-day, multi-agency collaborat...ate and local agencies with large and complex inci...a vital, ad-hoc, secure mobile communications in... NORFOLK, Va., July 25 /PRNewswire/ -- Dataline L...
(Date:7/25/2008)...The Elekta Family of Companies will,showcase their...2008,American Association of Physicists in Medicin...nt forces of Elekta, IMPAC and CMS are delivering,...ry solutions that,streamline the treatment process...ll as enhance clinician efficiency., "Our recent ...
(Date:7/25/2008)... delivers immediate cost savings for http://www.l... language interpreters] to firms switching langua... Washington, D.C. (Vocus)....com/index.html [(Language Learning Enterprises, ...slation, and language instruction services to thou...
Breaking Medicine News(10 mins):Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 3Health News:Dataline Announces Participation in Operation Golden Phoenix 2Health News:Dataline Announces Participation in Operation Golden Phoenix 3Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 3
...rk chocolate consumption to improved insulin sensi...ls that three ounces of dark chocolate a day for s...f 10 percent and improves insulin sensitivity in p...udied 20 people, 10 men and 10 women, each were as...
...six million people were infected with HIV by 2004.... at a high of 14 percent. South Africa 's total po...ounced by South African Health Department is far h... given by the official state statistics agency, St...
...tonseed has been found be increase the effectivene...ents. This could prove beneficial in cancer treatm....D., co-director of the Molecular Therapeutics Pro...entre, discovered gossypol, a compound derived fro...
...tify and treat patients with alcohol disorders hav... Abuse and Alcoholism, US. Alcohol disorders often...effective methods for early screenings and interve...ns and patients. When correct method of screening ...
Other Medicine News:Health News:Over Six Million HIV Infected People In South Africa- Finds A Survey 2Health News:Over Six Million HIV Infected People In South Africa- Finds A Survey 3
(Date:7/23/2008)... ASPS Study Finds Some Areas of the Body Have ...EIGHTS, Ill., July 23 /PRNewswire-USNewswire/ -- F...through liposuction was found to be,an excellent s...rations,than other areas of the body, reports a Br...tructive Surgery(R), the official medical journal ...
(Date:7/23/2008)... SEATTLE, July 23 /- De...d that it expects the Independent Data,Monitoring ...erim analysis,of overall survival relating to the ...te AdenoCarcinoma Treatment, also known as D9902B)...VENGE is the Company,s investigational,active cell...
(Date:7/22/2008)... BRISBANE, Australia, July 22 /PRNewswire-Firs...ed late yesterday, the Board of Progen,Pharmaceuti...ced that it,had discontinued the PI-88 phase 3 stu... direction to develop its existing portfolio of co...ire additional compounds and,opportunities through...
(Date:7/22/2008)... MINNEAPOLIS, July 22 /- Nonin Me...ring solutions for more than 20 years, has entered...technology to measure,regional oxygen saturation. ...y is the continuous monitoring of the regional blo... Early testing data and outcomes from an ongoing ...
Breaking Medicine Technology:Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2CafePress Supports Stand Up To Cancer With Online Store to Help Raise Awareness and Funds for Research 22059 1CafePress Supports Stand Up To Cancer With Online Store to Help Raise Awareness and Funds for Research 22059 2Faith Haines Kolb Joins PROMETRIKA as Senior Director of Clinical Operations and Data Management 6052 1Faith Haines Kolb Joins PROMETRIKA as Senior Director of Clinical Operations and Data Management 6052 2Faith Haines Kolb Joins PROMETRIKA as Senior Director of Clinical Operations and Data Management 6052 3First successful reverse vasectomy on endangered species performed at the National Zoo 3662 1First successful reverse vasectomy on endangered species performed at the National Zoo 3662 2First successful reverse vasectomy on endangered species performed at the National Zoo 3662 3Wavelets crunch through doctors day long struggle to diagnose brain tumors 22053 1Wavelets crunch through doctors day long struggle to diagnose brain tumors 22053 2
... Tolerance Support Development,of Omega DUROS Cont...2, 2007 /PRNewswire/ -- Intarcia,Therapeutics, Inc...ay announced final results from a Phase 2 study of...atment-naive patients,with genotype 1 chronic hepa...eron in combination with ribavirin is well tolerat...
...11, 2007 (PRIME NEWSWIRE) --,Hana Biosciences (Nas...advancing cancer care, will present preclinical da...the American Association,for Cancer Research 100th...California. , Abstract No. 2210: "Combining talotr...ll lung cancer (NSCLC) athymic nude,mice xenograft...
Other Medicine Technology:Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 2Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 3Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 4Hana Biosciences Announces Data to be Presented On Talvesta,(Talotrexin) for Injection at The American Association for Cancer,Research Annual Meeting 2Hana Biosciences Announces Data to be Presented On Talvesta,(Talotrexin) for Injection at The American Association for Cancer,Research Annual Meeting 3
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
Medicine Products: